Beam isn't as far along as some of its CRISPR-focused peers. The company is evaluating four candidates in phase 1/2 clinical testing targeting the rare genetic disorders sickle cell disease ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Sickle cell disease research news: STAT looks at new CRISPR-based treatment possibilities, and asks when sickle cell gene therapies will become widely available. For more on Oxbryta, Adakveo ...

Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can go ahead, after the FDA lifted a hold on a review. The companies had applied ...

Last month, the one-time treatment won its first FDA nod for treating sickle cell disease. Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is now approved in the United Kingdom for ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease ... to be licensed using gene-editing tool Crispr, which earned its inventors the ...

LONDON — People in England with sickle cell disease will now be able to access the world’s first CRISPR-based medicine under a pricing and reimbursement agreement reached between U.K. health ...

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

Beam isn't as far along as some of its CRISPR-focused peers. The company is evaluating four candidates in phase 1/2 clinical testing targeting the rare genetic disorders sickle cell disease ...